Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas
Thomas E. Witzig, Hui Tang, Ivana N.M. Micallef, Stephen M. Ansell, Brian K. Link, David J. Inwards, Luis F. Porrata, Patrick B. Johnston, Joseph P. Colgan, Svetomir N. Markovic, Grzegorz S. Nowakowski, Carrie A. Thompson, Cristine Allmer, Matthew J. Maurer, Mamta Gupta, George Weiner, Ray Hohl, Paul J. Kurtin, Husheng Ding, David LoegeringPaula Schneider, Kevin Peterson, Thomas M. Habermann, Scott H. Kaufmann
Dive into the research topics of 'Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas'. Together they form a unique fingerprint.